Avant Diagnostics, Inc.’s ("AVANT")(AVDX) data-generating technology allows patient-focused precision medicine to become a reality in cancer treatment. Both pharmaceutical companies developing drugs and oncologists find that Avant’s Theralink® assay enables clear decision making on the effectiveness of drugs for an individual patient’s cancer treatment.
Enabling Physicians to make Personalized Treatment Recommendations for Cancer Patients
Avant provides personalized medicine data through its TheraLink® assays, initially for breast cancer, to assist clinical oncologists in identifying likely responders, for over 70 FDA-approved drug treatment regimens. Avant is the leading developer of phospho-proteomic technologies for measuring the activation status of key signaling pathways, with applications across multiple cancer types, including breast, colorectal and pancreatic, that are instrumental in the development of companion diagnostics for molecular-targeted therapies. Theralink®, was developed to empower community physicians and clinical trial investigators with actionable information to make time sensitive treatment decisions for their patients. Theralink® was designed to inform physicians which treatments are likely to be effective for their patients at any given moment in time, and also identify which treatments are unlikely to be effective. This information has the potential to improve treatment efficacy and reduce side effects by foregoing ineffective therapy.
Science Backed by Strong Leadership
Meet the team that is the driving force behind our success.